HPV Vaccination Best Practices Learning Collaborative

HPV Infographic

Download the HPV Vaccination Best Practices Learning Collaborative Summary Report and Lessons Learned White Paper here

Download White Paper

AMGA and the National HPV Vaccination Roundtable launched an 18-month learning collaborative to improve HPV vaccination rates among adolescents served by medical groups and integrated health systems.  This Collaborative is based off the successful work undertaken in AMGA’s Adult Immunization Best Practices Learning Collaborative which resulted in 5.5 million vaccinations administered or documented over a three year period. Funding for the learning collaborative was made possible by the Office of Infectious Disease and HIV/AIDS Policy (OIDP) via the Centers for Disease Control and Prevention under CFDA # 93.421 - Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health, Cooperative Agreement grant number 6 NU38OT000283-02-01.

Eight healthcare organizations were recruited to participate in the collaborative and to implement best practice interventions and strategies.

What We Already Know

Fourteen-million Americans acquire HPV infections each year. We do not know what infections will clear and which infections will not. We do know that the HPV vaccine includes strains that cause over 90% of HPV cancers, mitigating patient risk. Approximately 92 people each day are diagnosed with an HPV-attributable cancer. These patients and their families face the emotional impact of a cancer diagnosis, the challenges of cancer treatment, and the possibility of death. Health systems with missions to improve health, provide high-quality care, and serve their communities have been caring for these patients, as well as managing the high financial costs that accompany cancer care. Health systems are well positioned to expedite HPV vaccine uptake and help eliminate HPV cancers.


We have convened an advisory committee of industry and clinical experts that will provide guidance to the Collaborative on the development of objectives and educational content. The committee includes:

  • Tammy Beckham, DVM, Ph.D.
    Associate Director, Resilient Supply Chain and Shortages Prevention Program
    Food & Drug Administration

  • Ilka Chavez, M.P.A.
    Chief of Operations and Management, National Vaccine Program Office (NVPO)
    U.S. Department of Health and Human Services

  • Kara Elam, Ph.D., M.P.H., M.S.
    Research and Policy Strategist
    Office on Women's Health

  • Melissa Gilkey, Ph.D.
    Assistant Professor, Department of Health Behavior
    University of North Carolina’s Gillings School of Global Health

  • Jonathan Hill, M.P.H.
    Public Health Analyst
    Centers for Disease Control and Prevention
  • Sarah Kobrin, Ph.D., M.P.H.
    Chief of Health Systems and Research Branch
    National Cancer Institute

  • Jason Maxwell, M.D.
    Department Chair of Pediatrics and Practices
    HealthPartners, Como Clinic

  • Kristin Oliver, M.D., M.H.S.
    Assistant Professor
    Icahn School of Medicine at Mount Sinai, Department of Environmental Medicine and Public Health, Department of Pediatrics

  • Andrea Polkinghorn, B.S.N., RN-BC
    Immunization Strategy Leader
    Sanford Health

  • Melinda Wharton, M.D., M.P.H.
    Associate Director for Vaccine Policy
    NCIRD at Centers for Disease Control and Prevention


If you have questions or need further information, contact Erin Leaver-Schmidt at eleaver-schmidt@amga.org or by phone at 703.838.0033 ext. 390.